Welcome to our dedicated page for SAB Biotherapeutics news (Ticker: SABS), a resource for investors and traders seeking the latest updates and insights on SAB Biotherapeutics stock.
SAB Biotherapeutics, Inc. (NASDAQ: SABS) is a clinical-stage biopharmaceutical company pioneering in the development and commercialization of fully human polyclonal antibodies using its proprietary DiversitAb™ platform. Unlike traditional methods involving human plasma or serum, SAB leverages genetically engineered transchromosomic cattle (Tc Bovine™) to produce large volumes of human antibodies (immunoglobulin G) in response to specific antigens.
The company's core technologies aim to provide novel therapies for a wide range of immune and autoimmune disorders, including its lead asset SAB-142, which targets type 1 diabetes (T1D). SAB-142 is a human anti-thymocyte immunoglobulin designed to modulate the body's immune response, potentially delaying the onset and progression of T1D. This innovative approach has shown promise in early clinical trials, with Phase 1 studies demonstrating safety and biological activity without the adverse reactions commonly associated with animal-derived therapies.
Recent achievements include the FDA granting Breakthrough Therapy and Fast Track Designations to SAB-176, a fully human polyclonal antibody targeting multiple strains of Influenza A and B. This reflects the potential of SAB's platform to address unmet medical needs swiftly and effectively.
SAB is actively pursuing multiple projects and partnerships to expand its clinical pipeline. Notable collaborations include a pharmacokinetic and safety study for SAB-176, conducted in partnership with the Henry Jackson Foundation and the NMRC Clinical Trials Center. Additionally, SAB’s ongoing Phase 1 clinical trial for SAB-142 has successfully completed dosing the third cohort with no observed serum sickness.
Financially, SAB reported positive results for Q1 2024, with sufficient cash reserves expected to fund operations into 2026, assuming the exercise of outstanding Tranche B warrants. The company's strategic relocation of its headquarters to Miami, FL, and the recent appointment of Dr. Jay Skyler to its Board of Directors underscore its commitment to T1D research and treatment.
SAB Biotherapeutics continues to engage with the scientific and investment communities, providing regular updates on its progress and maintaining transparency in its forward-looking statements. As a pioneer in biopharmaceutical innovation, SAB is poised to make significant contributions to the treatment of immune and autoimmune disorders.
SAB BIO (SABS) reported Q3 2024 financial results and provided updates on its SAB-142 Type 1 diabetes program. The company completed Phase 1 enrollment with no observed serum sickness and remains on track for topline data readout by year-end. Cash position stood at $30.4 million as of September 30, 2024. Q3 net loss widened to $10.3 million ($1.12 per share) from $5.1 million ($0.97 per share) year-over-year. R&D expenses increased to $7.8 million from $4.0 million, while G&A expenses rose to $3.5 million from $2.6 million in Q3 2023.
SAB BIO (Nasdaq: SABS) announced that Chairman and CEO Samuel J. Reich will participate in a fireside chat at the 2024 Guggenheim Securities Healthcare Innovation Conference. The event will take place on November 11, 2024, at 3:00pm EST in Boston, MA. SAB BIO is a clinical-stage biopharmaceutical company developing a novel human anti-thymocyte immunoglobulin (hIgG) therapy aimed at delaying the onset or progression of type 1 diabetes. The fireside chat will be accessible via webcast, with a recording available through the company's website events section.
SAB BIO (Nasdaq: SABS), a clinical-stage biopharmaceutical company, announced that its Chairman and CEO, Samuel J. Reich, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference. The event is scheduled for September 18th, 2024, at 8:00 am ET in New York, NY.
SAB BIO is developing a novel immunotherapy platform focusing on a human anti-thymocyte immunoglobulin (hIgG) to delay the onset or progression of Type 1 Diabetes (T1D). The company has provided a webcast registration link for those interested in attending virtually. Additionally, a recording of the webcast will be available through the 'Events' section of SAB BIO's investor relations website.
SAB BIO (Nasdaq: SABS) has provided an update on its SAB-142 clinical trial at the European Association for the Study of Diabetes Annual Meeting. The company has completed Phase 1 enrollment of all planned cohorts in healthy volunteers and is now enrolling patients with type 1 diabetes in the last cohort. Notably, the target dose of 2.5mg/kg was completed with no observation of serum sickness.
SAB-142, a first-in-class human anti-thymocyte immunoglobulin, is being developed to delay the onset and progression of type 1 diabetes. The Phase 1 trial aims to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. The company remains on track for a topline Phase 1 data readout by the end of the year.
SAB BIO (Nasdaq: SABS), a clinical-stage biopharmaceutical company, has announced its participation in the European Association for the Study of Diabetes 60th Annual Meeting on September 9, 2024, in Madrid. The company's Executive Vice President and Chief Medical Officer, Alexandra Kropotova, MD, MBA, will present on the topic 'Protecting pancreatic beta cells with multi-target, multi-epitope immunotherapy: SAB-142'.
SAB BIO is developing a novel immunotherapy platform using human anti-thymocyte immunoglobulin (hIgG) to delay the onset or progression of type 1 diabetes (T1D). The presentation will take place during the INNODIA EASD Symposium at 8:45 am in the Beijing Hall of the EASD Symposium, highlighting the company's innovative approach to T1D treatment.
SAB BIO (Nasdaq: SABS) reported its Q2 2024 financial results and provided company updates. Key highlights include:
1. FDA clearance for SAB-142 IND application
2. Appointment of Lucy To as CFO
3. Founding of a new Clinical Advisory Board
4. Cash position of $37.3 million as of June 30, 2024
5. R&D expenses increased to $6.8 million in Q2 2024
6. Net loss of $7.3 million for Q2 2024
The company reaffirmed its cash runway into 2026 and remains focused on developing SAB-142 for delaying or stopping the progression of type 1 diabetes. SAB-142 is on track for a topline Phase 1 data readout by year-end.
SAB Biotherapeutics (Nasdaq: SABS) has announced the formation of a clinical advisory board to guide the development of SAB-142, their leading therapeutic candidate for type 1 diabetes (T1D). The board comprises world-leading experts in T1D therapies and will provide strategic direction, insights on clinical protocols, and support research initiatives. SAB-142 is a human anti-thymocyte immunoglobulin (hIgG) designed to delay the onset or progression of T1D.
Samuel J. Reich, Chairman and CEO of SAB BIO, emphasized the potential of SAB-142 to be a best-in-class human antibody treatment for safe, reliable life-long dosing, potentially delaying clinical onset and progression of T1D. The advisory board includes prominent experts from institutions such as Cardiff University, University of Florida, University of California, University of Melbourne, and Katholieke Universiteit Leuven.
SAB Biotherapeutics (Nasdaq: SABS) has appointed Lucy To as Chief Financial Officer, effective August 12, 2024. With over 18 years of investment banking and strategic operational expertise, Ms. To will lead corporate finance, strategy, and strategic business relationships at SAB. The company is developing human anti-thymocyte immunoglobulin (hIgG) to delay the onset or progression of type 1 diabetes (T1D).
SAB's CEO, Samuel J. Reich, expressed confidence in Ms. To's ability to contribute to the company's upcoming milestones for SAB-142, their lead candidate. Ms. To, previously a Managing Director in the Healthcare Investment Banking Group at Wells Fargo, brings extensive experience in M&A, IPOs, and other equity and debt financings in the healthcare sector, with transactions totaling over $50 billion.
SAB Biotherapeutics, now rebranded as SAB BIO, has announced a new name, logo, and website updates. Despite the cosmetic changes, the company's stock symbol remains SABS. This rebranding aligns with SAB BIO's mission to address immune and autoimmune disorders, specifically type 1 diabetes (T1D), using their unique immunotherapy platform. CEO Samuel J. Reich emphasized the importance of this transformation in representing SAB BIO's focus on developing therapies to slow disease progression in T1D patients. The announcement comes ahead of their presentation at the American Diabetes Association 84th Scientific Sessions in Orlando. Additionally, the company reiterated its financial outlook for 2024 and upcoming milestones, including a Phase 1 study data readout for their lead candidate, SAB-142.
SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company, will present at the American Diabetes Association (ADA) 84th Scientific Sessions from June 21-24, 2024, in Orlando, Florida. The presentation will focus on SAB's novel immunotherapy platform, specifically its human anti-thymocyte immunoglobulin (hIgG) aimed at delaying the onset or progression of type 1 diabetes (T1D). Eric Sandhurst, Ph.D., SAB's Senior Program Manager, will present a poster on June 23, 2024, from 12:30 PM to 1:30 PM, detailing the IND-Enabling Assessment of Tolerance and Safety for SAB-142, a first-in-class fully human anti-thymocyte immunoglobulin. The poster will also be published online in the journal Diabetes® and available for viewing throughout the ADA sessions.
FAQ
What is the current stock price of SAB Biotherapeutics (SABS)?
What is the market cap of SAB Biotherapeutics (SABS)?
What is SAB Biotherapeutics, Inc.?
What is the DiversitAb™ platform?
What is SAB-142?
What recent achievements has SAB Biotherapeutics reported?
Who are SAB's key partners?
Where is SAB Biotherapeutics headquartered?
What is the financial outlook for SAB Biotherapeutics?
How does SAB-142 differ from rabbit-derived ATG?
What is the focus of SAB's current clinical trials?
How can I learn more about SAB Biotherapeutics?
